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Recombinant cross-packaging of adeno-associated virus (AAV) genome of one serotype into
other AAV serotypes has the potential to optimize tissue-specific gene transduction and
expression in the heart. To evaluate the role of AAV1 to 5 virion shells on AAV2 transgene
transduction, we constructed hybrid vectors in which each serotype capsid coding domain was
cloned into a common vector backbone containing AAV2 replication genes. Constructs were
tested for expression in: (1) adult murine heart in vivo using direct injection of virus, (2) neonatal
and adult murine ventricular cardiomyocytes in vitro, and (3) adult human ventricular
cardiomyocytes in vitro, using green fluorescent protein (GFP) as the measurable transgene.
Serotype 1 virus demonstrated the highest transduction efficiency in adult murine cardiomyo-
cytes both in vitro and in vivo, while serotype 2 virus had the greater transduction efficiency in
neonatal cardiomyocytes in vitro. Prolonged in vivo myocardial GFP expression was observed for
up to 12 months using serotype 1 and 2 vectors only. In human cardiomyocytes, serotype 1 vector
was superior in transduction efficiency, followed by types 2, 5, 4, and 3. These data establish a
hierarchy for efficient serotype-specific vector transduction in myocardial tissue. AAV1 serotype
packaging results in more efficient transduction of genes in the murine and human adult heart,
compared to other AAV serotypes. Our results suggest that adult human cardiac gene therapy
may be enhanced by the use of serotype 1-specific AAV vectors.
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Recombinant vectors derived from adeno-associated virus
(AAV) are attractive tools for human gene therapy, as
they are nonpathogenic and can establish long-term
expression in a variety of tissues, including the heart
[1]. Adeno-associated viruses are members of the parvo-
virus family and have in common similar size, structure,
and dependence on a helper virus for replication and
gene expression [2]. To date, eight serotype isolates of
AAV have been reported, and their genomes appear to be
organized in a similar configuration of structural and
replication genes [3,4]. Of these, AAV serotypes 2, 3, 5,
and 6 were discovered from human cells, while AAV
serotypes 1 and 4 were found to have a nonhuman
primate origin [5]. AAV vectors have come to the fore-
front of gene therapy research due to several attractive
features, including lack of cytotoxicity, ability to trans-
duce both dividing and nondividing cells, long-term
transgene expression, and ability to be generated into
high-titer virus preparations in the laboratory.
AAV2 has been the most frequently employed adeno-
associated virus vector for gene transfer experiments to
date. However, this vector has limitations in the heart.
First, AAV2-based vectors are generally thought to be
inefficient at transducing myocardial cells in vitro and in
vivo [6], and second, AAV2-vector-mediated gene transfer
may be limited by prevalent neutralizing antibody in
humans due to prior exposure to wild-type virus [7]. For
these reasons, alternative hybrid vectors that utilize the
capsid structure of one AAV serotype in conjunction with
the replication genes of another AAV serotype hold
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promise for improved gene transduction efficiency. The
present study examined whether specific AAV serotype
cross-packaging would optimize human and/or murine
myocardial gene transduction. Specifically, we asked the
question whether packaging of the AAV2 genome into
the virions of AAV1-5 would yield a superior gene therapy
vector for myocardial transduction.
To test the capacity of recombinant AAV (rAAV) sero-
types for efficient myocardial transduction, we used five
cross-packaged vectors to infect different kinds of cardio-
myocytes using identical numbers of genomic particles
(GP) per cell. We produced rAAV cross-packaged vectors
by triple-plasmid transfection, purified them by iodixa-
nol gradient centrifugation, and titered them as previ-
ously described [8,9]. Vectors contained the inverted
terminal repeats (ITRs) of AAV2, with green fluorescent
protein (GFP) [10] as the transgene under the control of
the cytomegalovirus promoter and were packaged using
the capsid genes of AAV1-5. We determined particle
number by real-time polymerase chain reaction and
injected preparations had at least 1  1011 GP/ml.
Primary adult mouse cardiomyocytes survive in vitro
for approximately 72 h before morphologic changes and
cell death ensue. For adult Balb/C mouse cardiomyo-
cytes (isolated from 8-week-old animals), we infected
separate cultures of 1  105 primary cells with 4  108
GP of each rAAV serotype in a total volume of 200
Al (M.O.I. of 4000 GP/cell), 2 h after cell isolation [11]
and plating. At 12-h intervals from 12 to 72 h after
infection, we fixed the cells in 4% paraformaldehyde
and tested for GFP immunofluorescence. Serotype 1
(rAAV1) vector produced the highest transduction levels
in adult mouse cardiomyocytes (12% of cells staining
positive for GFP), and the zenith of transgene expression
occurred at 48 h and continued for the life span of the
cells (Fig. 1A). In contrast, rAAV2-infected cells demon-
strated approximately 4% positive staining for GFP.
rAAV5, 4, and 3 displayed minimal transduction of
adult cardiomyocytes in vitro (<1% of cells staining
positive for GFP).
Primary mouse neonatal cardiomyocytes survive in
vitro for approximately 8 days before cell rounding, de-
tachment, and death. For neonatal Balb/C mouse cardio-
myocytes (isolated from 1-day-old animals), we infected
separate cultures of 1  106 primary cells with 4  109 GP
of each rAAV serotype in a total volume of 400 Al (M.O.I.
of 4000 GP/cell), 12 h after cell isolation [12] and plating.
We fixed the neonatal cells in 4% paraformaldehyde at
24-h intervals from 1 to 7 days after infection and tested
for GFP immunofluorescence. In contrast to adult cardio-
myocytes, in which serotype 1 AAV-GFP vector had high-
est transduction efficiency, neonatal heart cells were
most efficiently transduced by serotype 2 AAV-GFP vector
(Fig. 1B). rAAV1 vector transduced neonatal cardiomyo-
cytes at 67% the efficiency of rAAV2 vector (1.2  105
positive cells in 1  106 total cells (12%) for rAAV1
compared to 1.8  105 positive cells in 1  106 total cells
(18%) for rAAV2). Maximal transgene expression was
achieved at 96 h and continued for the life of the cells.
Serotype 5-infected cells showed 3% GFP positivity at 7
days, while serotypes 3 and 4 displayed <1% GFP staining
at all measured time points.
FIG. 1. rAAV-mediated gene transfer into cardiomyocytes. (A) Graph of gene
transduction efficiency of adult mouse cardiomyocytes in vitro by rAAV1 – 5 as
a function of time after infection. (B) Graph of gene transduction efficiency of
neonatal mouse cardiomyocytes in vitro by rAAV1 –5 as a function of time
after infection. (C) Graph of gene transduction efficiency of adult human
ventricular cardiomyocytes as a function of time after infection. GFP
expression was analyzed by immunofluorescence using rabbit anti-GFP
antibody and goat anti-rabbit IgG –FITC secondary antibody. For in vitro
cardiomyocyte experiments, four separate preparations of each rAAV
serotype were tested in quadruplicate for each cell type at each time point.
Positive-staining cells were counted, at a magnification of 100, as a
percentage of total cells over six 0.5-mm2 fields and averaged. All data are
presented as means F SEM.
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Primary human adult cardiomyocytes survive in vitro
for approximately 72 h. Twenty male patients (mean age
65.6 years; range 51-78 years) who were undergoing
coronary artery bypass surgery underwent left ventricular
biopsy prior to induction of cardiopulmonary bypass, as
previously described [13]. This study was approved by the
University of California, San Diego Institutional Review
Board, and all patients had given written informed con-
sent for biopsy. We performed cardiomyocyte isolation
and culturing as described by Bird et al. [14]. We infected
separate cultures of cells (1  105) with 4  108 GP of each
rAAV serotype in a total volume of 200 Al (M.O.I. of 4000
GP/cell), 2 h after cell isolation and plating, and later
fixed them in 4% paraformaldehyde at 12-h intervals
after infection up to 72 h and tested for GFP immuno-
fluorescence. We found maximal vector transduction in
human cardiomyocytes at 60 h postinfection for rAAV1-
infected cells, with 10% of cells staining positive for GFP
(Fig. 1C). Other rAAV serotypes demonstrated less trans-
duction at the same time interval, with percentage cells
staining with GFP being rAAV2, 5%, and rAAV3, 4, and 5,
<1%.
To investigate in vivo cardiac transduction efficiency,
we injected the five different serotypes of rAAV-GFP into
the left ventricular apex of the mouse through an oblique
thoracotomy in 10-week-old Balb/C mice in separate
experiments. We injected a total of 2  1010 GP of
cross-packaged AAV serotypes 1-5, each in 100 Al PBS,
intramyocardially with a 28-gauge needle into three sites
along the anterior apical left ventricular wall (40 animals
for each serotype, 8 animals for each time point). Twelve
control animals received an equivalent volume of PBS.
We assayed the hearts for GFP protein amount by West-
ern blotting and immunofluorescence at 2-week and 1-,
3-, 6-, and 12-month intervals after gene transfer. Two
weeks after surgery, small numbers (<1%) of GFP-positive
cardiomyocytes were detected in the area of injection for
rAAV1 and rAAV2. Transgene expression for all serotypes
was greatest at 1 month after transduction. By 1 month
after rAAV1 injection, approximately 40% of the cardio-
myocytes in an area of 5 mm around the injection site
were GFP positive, while 25% of the cardiomyocytes in
the same size area for rAAV2-injected hearts were GFP
positive (Fig. 2A). rAAV3-, 4-, and 5-transduced hearts
displayed less than 3% GFP-positive cells at 1 month
postinfection (Figs. 2A and 2B). GFP expression persisted
in hearts that had been infected with rAAV1 and rAAV2
for up to 12 months, although both serotype-injected
hearts displayed progressive diminution in transgene
expression between 6 and 12 months (Figs. 2B and 2C).
By 12 months, GFP-positive cells in rAAV1- and rAAV2-
transduced hearts were less than 10% at the site of
injection. At each time point, more than 99% of cells
staining had the histologic appearance of cardiomyo-
cytes, while the remaining approximately 1% of cells
had the histologic appearance of vascular endothelium.
The results from Fig. 2 also indicate a distinct gradient
of tropism for murine heart among the five tested sero-
types. Transduction of rAAV1 vectors led to higher levels
of GFP protein in murine whole-heart extracts, compared
to serotypes 2–5. Taken together, the results of GFP
immunofluorescence staining and Western blotting indi-
cate: (1) an enhanced mouse myocardial tropism for
rAAV1 compared to other serotypes and (2) prolonged
(12 month) transgene expression with rAAV1 and, to a
lesser degree, rAAV2.
The ability to deliver therapeutic genes to the heart in
high concentration with stable expression holds potential
for the treatment of numerous cardiovascular diseases,
including ischemic cardiomyopathy, arrhythmia, and
congestive heart failure. In this report, we have demon-
strated that a rAAV1 virion carrying a transgene flanked
by AAV2 ITRs is a superior vector for transduction of adult
cardiomyocytes, both in vitro and in vivo, compared to
other AAV serotype viruses. Our results demonstrate that,
without modifying the gene expression cassette, the
capsid composition of the AAV serotype appears to affect
vector transduction significantly enough to produce var-
iations in the measurement of transgene expression
within the heart and within cardiomyocytes in vitro.
The production of vectors based on AAV serotypes
other than AAV2 is a technology that is still in its early
stages. While the first generation of vectors built exclu-
sively from components of AAV2 was reported almost 20
years ago [15], it was only recently that recombinant
viruses carrying a capsid from a serotype other than
AAV2 were reported [16]. Our goal in testing different
serotypes of AAV in the heart was to retain the favorable
biology of AAV2 in terms of stable transgene expression,
while modifying viral entry pathways to improve trans-
duction frequency. When normalized for equivalent
doses of administered vector genomes, rAAV1 performs
better in the adult heart and in adult cardiomyocytes
than rAAV2, whereas the opposite is true for neonatal
cardiomyocyte transduction. This probably reflects dif-
ferential expression of receptors for each serotype virus in
adult versus neonatal heart cells.
The mechanism of viral entry and binding to cells is
known for only a few AAV serotypes. The primary recep-
tor for AAV2 is heparin sulfate proteoglycan, a molecule
present on most cell types [17]. Further analyses have
determined that the coreceptors for this virus are aVh5
integrin and human fibroblast growth factor receptor–1
[18,19]. In contrast, serotypes 4 and 5 utilize sialic acid
for cellular transduction but differ in sialic acid linkage
specificity, which probably reflects that their tissue tro-
pism is distinct from that of AAV2 and each other [20].
Recently, platelet-derived growth factor receptor has
been identified as a putative receptor for AAV5 transduc-
tion [21]. The receptor for AAV1 is unknown; however,
AAV1 is known to transduce skeletal muscle more effi-
ciently than AAV2 [3]. AAV3 has 82% identity at the
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nucleotide level with AAV1 and binds heparin sulfate
proteoglycan in vitro [22], although its in vivo receptor is
not known. Recently, AAV6 has been isolated from con-
taminated human adenovirus preparations, and it has
been found to be a recombinant product between AAV1
and AAV2 [23]. The tropism and receptors used by this
serotype virus are unknown.
AAV1 vectors may be advantageous compared to
AAV2 vectors in human myocardial gene therapy, not
only because of superior transduction efficiency, but also
because of the lack of neutralizing antibodies to AAV1 in
human serum. While 80% of the human population has
been shown to contain monospecific neutralizing anti-
bodies to AAV2 (presumably due to previous infection
with this virus), few monospecific antibodies to AAV1
have been detected in the human population (presum-
ably due to the fact that AAV1 is simian in origin) [24].
Since AAV1 is derived from a nonhuman source, hybrid
viruses utilizing the capsid structure of AAV1, while
retaining the replication genes of AAV2, may allow for
effective transgene expression in humans without signif-
icant immune response directed against the vector itself.
In summary, this study is the first step in the long-
term goal of identifying vector capsid domains responsi-
ble for optimal cardiomyocyte entry, receptor binding,
and organ-specific tropism. Additional efforts to under-
stand the role of serotype-specific vector components will
not only facilitate a comprehensive understanding of
FIG. 2. (A) Gene transfer into cardiomyocytes in vivo after intramyocardial injection of rAAV serotypes 1–5. Left: Photomicrographs of immunostained mouse
hearts 1 month after intramyocardial injection with 2  1010 GP of rAAV1 –5 vectors with GFP as the measurable transgene. Hearts were snap-frozen in OCT
compound and continuous short-axis sections were taken at 5 Am thickness to incorporate the distal 0.5 cm of the heart from base to apex. Usually the lower
middle sections incorporated the needle tracks. Positive-staining cells were counted by fluorescence microscopy at a magnification of 50 in each section (50 total
sections probed with GFP antibody, 50 adjacent sections with no primary antibody as control). Right: Photomicrographs of phase-contrast images of mouse
hearts from the same sections shown on the left to view cell density. Bar, 100 Am. (B) Quantitation of GFP immunostaining at different times after
intramyocardial injection of rAAV vector serotypes 1–5. The mean number of positive cells from each heart (sectioned as above) is reported as the percentage of
positive cells in relation to the total number of myocytes counted. Data are presented as means F SEM. Four separate preparations of each rAAV serotype were
tested in duplicate at each time point. Note that rAAV serotype 1 showed greatest transduction efficiency and highest level of transgene expression at 1 year
compared to other serotypes. (C) Western blot quantitation of GFP (using 50 Ag of total protein isolated from heart samples and a monoclonal anti-GFP antibody
followed by NBT/BCIP substrate development) in murine heart at time intervals up to 1 year after intramyocardial injection of rAAV serotype 1 –5 vectors.
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efficient vector transduction but also potentially allow
the generation of optimized new hybrid AAV vectors. Our
results suggest that recombinant AAV vectors packaged in
a serotype 1 capsid have enhanced ability to transduce
adult cardiomyocytes efficiently in vivo and in vitro and as
such, may represent an important vector for myocardial
gene therapy. The technology for production of vectors
based on serotypes of AAV paves the way for a much
broader and more efficient application of the AAV vector
system in the heart.
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